Ironwood Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IRWD)

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its earnings results on Tuesday, July, 30th. The biotechnology company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.15. The biotechnology company had revenue of $102.22 million for the quarter, compared to analysts' expectations of $89.28 million. The firm's revenue for the quarter was up 26.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.22) EPS. View Ironwood Pharmaceuticals' Earnings History.

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals updated its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $370-390 million, compared to the consensus revenue estimate of $374.63 million.

11 equities research analysts have issued twelve-month price targets for Ironwood Pharmaceuticals' shares. Their predictions range from $12.00 to $20.00. On average, they expect Ironwood Pharmaceuticals' stock price to reach $15.05 in the next year. This suggests a possible upside of 58.9% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.

Media stories about IRWD stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Ironwood Pharmaceuticals earned a daily sentiment score of -1.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Ironwood Pharmaceuticals.

Some companies that are related to Ironwood Pharmaceuticals include Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), The Medicines (MDCO), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Allakos (ALLK), Nektar Therapeutics (NKTR), FibroGen (FGEN), Evotec (EVTCY), Alkermes (ALKS), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO) and BridgeBio Pharma (BBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Allergan (AGN) and Continental Resources (CLR).

Ironwood Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.97%), Brown Capital Management LLC (7.88%), Janus Henderson Group PLC (4.85%), Janus Henderson Group PLC (4.85%), EcoR1 Capital LLC (2.99%) and Westfield Capital Management Co. LP (1.53%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

IRWD stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Canada Pension Plan Investment Board, D. E. Shaw & Co. Inc., Morgan Stanley, Cubist Systematic Strategies LLC, Marshall Wace LLP, BNP Paribas Arbitrage SA and NumerixS Investment Technologies Inc. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

IRWD stock was acquired by a variety of institutional investors in the last quarter, including Brown Capital Management LLC, Peregrine Capital Management LLC, Nuveen Asset Management LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, Vanguard Group Inc., Westfield Capital Management Co. LP and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $9.47.

Ironwood Pharmaceuticals has a market capitalization of $1.48 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe.View Additional Information About Ironwood Pharmaceuticals.

The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com/.

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]